Large volume re-irradiation for recurrent meningioma with pulsed reduced dose rate radiotherapy
Meningiomas comprise up to 30% of primary brain tumors. The majority of meningioma patients enjoy high rates of control after conventional therapies. However, patients with recurrent disease previously treated with radiotherapy have few options for salvage treatment, and systemic interventions have proven largely ineffective. The aim of this study was to determine whether pulsed reduced dose rate radiotherapy (PRDR) was well tolerated in a small cohort of patients with recurrent meningioma.
We retrospectively identified eight patients with recurrent intracranial meningioma treated with PRDR from April 2013 to August of 2017 at a single institution. All patients had radiographic and/or pathologic evidence of progression prior to treatment and had previously completed conventional radiotherapy. Acute and late toxicities were graded based on CTCAE 4.0.
Of eight patients, six had histologically confirmed atypical meningiomas upon recurrence. All patients were re-treated with IMRT at an apparent dose rate of 0.0667 Gy/min. Median time between radiation courses was 7.7 years. Median PRDR dose was 54 Gy in 27 fractions to a median volume of 261.6 cm3. Two patients (25%) had in field failure with a median follow up of 23.3 months. PFS at 6 months was 100%. All but one (87.5%) patient was still alive at last follow up. No patient experienced grade ≥ 2 acute or late toxicities.
PRDR re-irradiation was well tolerated and appeared effective for a small cohort of patients with recurrent meningioma previously treated with radiotherapy. A phase II trial to assess this prospectively is in development.
KeywordsMeningioma Re-irradiation Radiation therapy CNS toxicity
We thank Edward Bender, Ph.D., DABR. for his contribution to this work.
Conflict of interest
The authors declare that they have no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 6.Rogers L, Zhang P, Vogelbaum MA et al (2017). Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 129:1–13Google Scholar
- 7.Feng R, Che X, Hu J, Pan L, Cui D, Yang L (2013) Surgical treatment of recurrent torcular meningiomas: case report and review of the literature. J Neurol Surg A Cent Eur Neurosurg 74(Suppl 1):e266–e270Google Scholar
- 9.Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas. NCT02523014. https://clinicaltrials.gov/ct2/show/NCT02523014
- 11.Clark VE, Erson-Omay EZ, Serin A et al (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 24:1233009Google Scholar
- 17.Hall EJ, Giaccia AJ (2018) Radiobiology for the radiologist, vol 7. Kluwer, South HollandGoogle Scholar